Request Your Free White Paper Now:

"Duchenne Muscular Dystrophy - Global Clinical Trial Landscape"

Discover insights to new trends and findings in Duchenne Muscular Dystrophy clinical trials.

Duchenne Muscular Dystrophy is a rare genetic disorder characterized by progressive muscle weakness and skeletal degeneration, impacting approximately 1 in 5,000 males globally. The prevalence of Duchenne Muscular Dystrophy is higher in certain regions, with Europe, particularly Sweden and Norway, along with the US, Canada, and China reporting elevated rates. This emphasizes the considerable health burden associated with this condition, necessitating concerted efforts in research and treatment.

Since 2019, the global biotech and biopharmaceutical industry initiated around 300 clinical trials for Duchenne Muscular Dystrophy. North America and Europe collectively conducted over 60% of Duchenne Muscular Dystrophy trials, with the UK and the US leading in their respective regions. In contrast, the Asia-Pacific region, led by countries like Australia and Japan, contributed around 30% of Duchenne Muscular Dystrophy trials.

Explore the latest trends in Duchenne Muscular Dystrophy clinical trials and discover key findings and analysis from this comprehensive report.

Offered Free by: Novotech
See All Resources from: Novotech